EA201691521A1 - Антитела к интерлейкину-21 - Google Patents

Антитела к интерлейкину-21

Info

Publication number
EA201691521A1
EA201691521A1 EA201691521A EA201691521A EA201691521A1 EA 201691521 A1 EA201691521 A1 EA 201691521A1 EA 201691521 A EA201691521 A EA 201691521A EA 201691521 A EA201691521 A EA 201691521A EA 201691521 A1 EA201691521 A1 EA 201691521A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
methods
interleukin
warranted
autoimmune
Prior art date
Application number
EA201691521A
Other languages
English (en)
Other versions
EA033335B1 (ru
Inventor
Джулиан Дэвис
Фабио МАГРИНИ
Андреа Паула Мартин
Неелуфар Мозаффариан
Четанкумар Натварлал Пател
Оливер Шрёдер
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201691521A1 publication Critical patent/EA201691521A1/ru
Publication of EA033335B1 publication Critical patent/EA033335B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

Настоящее изобретение относится к сконструированным, гуманизированным антителам, которые обладают высокой аффинностью связывания и нейтрализуют ИЛ-21 человека, к способам применения указанных антител для лечения состояний, в которых оправданным является антагонистическое воздействие на ИЛ-21 или нейтрализация активности ИЛ-21, таких как аутоиммунные состояния, к композициям и способам получения указанных антител с помощью рекомбинантных методик и фармацевтическим композициям, содержащим указанные антитела.
EA201691521A 2014-03-21 2015-03-13 Антитело к интерлейкину-21 и его применение для лечения аутоиммунного состояния EA033335B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461968550P 2014-03-21 2014-03-21
PCT/US2015/020383 WO2015142637A1 (en) 2014-03-21 2015-03-13 Il-21 antibodies

Publications (2)

Publication Number Publication Date
EA201691521A1 true EA201691521A1 (ru) 2017-02-28
EA033335B1 EA033335B1 (ru) 2019-09-30

Family

ID=54141466

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201691521A EA033335B1 (ru) 2014-03-21 2015-03-13 Антитело к интерлейкину-21 и его применение для лечения аутоиммунного состояния

Country Status (24)

Country Link
US (1) US9394362B2 (ru)
EP (1) EP3119806B1 (ru)
JP (2) JP6053989B2 (ru)
KR (1) KR101859857B1 (ru)
CN (1) CN106061999B (ru)
AP (1) AP2016009450A0 (ru)
AR (1) AR099625A1 (ru)
AU (1) AU2015231777B2 (ru)
BR (1) BR112016019176A2 (ru)
CA (1) CA2939543C (ru)
CL (1) CL2016002281A1 (ru)
EA (1) EA033335B1 (ru)
EC (1) ECSP16075416A (ru)
ES (1) ES2774422T3 (ru)
IL (1) IL246909A0 (ru)
MA (1) MA39342B2 (ru)
MX (1) MX2016012120A (ru)
MY (1) MY177915A (ru)
NZ (1) NZ722518A (ru)
PE (1) PE20161221A1 (ru)
PH (1) PH12016501820A1 (ru)
SG (1) SG11201606705QA (ru)
TW (1) TWI646105B (ru)
WO (1) WO2015142637A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3128997T3 (da) 2014-04-08 2020-08-24 Boston Pharmaceuticals Inc Bindingmolekyler specifikke for il-21 og anvendelser deraf
US10654932B2 (en) 2015-10-30 2020-05-19 Genentech, Inc. Anti-factor D antibody variant conjugates and uses thereof
JP7010833B2 (ja) * 2016-03-31 2022-02-10 イーライ リリー アンド カンパニー Ｉｌ－２１抗体及びその使用
KR20210081322A (ko) 2018-08-02 2021-07-01 다인 세라퓨틱스, 인크. 근육 표적화 복합체 및 디스트로핀병증을 치료하기 위한 그의 용도
JP2022536898A (ja) 2019-06-12 2022-08-22 アスクジーン・ファーマ・インコーポレイテッド 新規ｉｌ－１５プロドラッグおよびその使用方法
EP4017594A1 (en) 2019-08-21 2022-06-29 Askgene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
IL309937A (en) * 2021-07-09 2024-03-01 Dyne Therapeutics Inc Muscle targeting complexes and their uses for the treatment of dystrophinopathy
WO2023283624A2 (en) * 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997029131A1 (en) * 1996-02-09 1997-08-14 Basf Aktiengesellschaft HUMAN ANTIBODIES THAT BIND HUMAN TNF$g(a)
ES2340280T3 (es) * 2003-03-14 2010-06-01 Wyeth Llc Anticuerpos dirigidos contra el receptor de il-21 humano y uso de los mismos.
ITRM20040586A1 (it) * 2004-11-29 2005-02-28 Giuliani Spa Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
AU2006341398B9 (en) * 2005-11-28 2012-02-02 Zymogenetics, Inc. IL-21 receptor antagonists
ES2409835T3 (es) * 2005-11-28 2013-06-28 Zymogenetics, Inc. Antagonistas de IL-21
US20090076249A1 (en) 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma
KR101603109B1 (ko) * 2007-12-07 2016-03-25 지모제넥틱스, 인코포레이티드 Ｉｌ-31에 특이적인 인간화된 항체 분자
CA2707026C (en) * 2007-12-07 2017-04-11 Zymogenetics, Inc. Anti-human il-21 monoclonal antibodies
EP2665750A1 (en) 2011-01-17 2013-11-27 Novo Nordisk A/S Il-21 ligands
WO2012164021A1 (en) * 2011-05-31 2012-12-06 Novo Nordisk A/S Il-21 epitope and il-21 ligands

Also Published As

Publication number Publication date
JP2016520088A (ja) 2016-07-11
MY177915A (en) 2020-09-25
AR099625A1 (es) 2016-08-03
EP3119806A4 (en) 2017-11-01
KR20160124166A (ko) 2016-10-26
WO2015142637A1 (en) 2015-09-24
CN106061999A (zh) 2016-10-26
EP3119806B1 (en) 2020-01-01
AP2016009450A0 (en) 2016-09-30
KR101859857B1 (ko) 2018-05-18
ECSP16075416A (es) 2018-05-31
US20150266954A1 (en) 2015-09-24
IL246909A0 (en) 2016-09-29
TW201623330A (zh) 2016-07-01
PH12016501820A1 (en) 2016-11-07
CA2939543C (en) 2018-01-16
MA39342B2 (fr) 2020-03-31
JP2017093435A (ja) 2017-06-01
EA033335B1 (ru) 2019-09-30
SG11201606705QA (en) 2016-09-29
TWI646105B (zh) 2019-01-01
CL2016002281A1 (es) 2017-06-23
CN106061999B (zh) 2020-07-31
AU2015231777A1 (en) 2016-08-18
MX2016012120A (es) 2016-12-09
BR112016019176A2 (pt) 2017-10-10
MA39342A1 (fr) 2018-03-30
US9394362B2 (en) 2016-07-19
ES2774422T3 (es) 2020-07-21
JP6373944B2 (ja) 2018-08-15
EP3119806A1 (en) 2017-01-25
CA2939543A1 (en) 2015-09-24
AU2015231777B2 (en) 2017-08-03
NZ722518A (en) 2017-12-22
JP6053989B2 (ja) 2017-01-11
PE20161221A1 (es) 2016-11-12

Similar Documents

Publication Publication Date Title
EA201691521A1 (ru) Антитела к интерлейкину-21
EA201891992A1 (ru) Химерные рецепторы и способы их применения
EA202091898A1 (ru) Антитела, нейтрализующие вирус иммунодефицита человека
EA201890630A1 (ru) Антитела против pd-1 и способы их применения
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
NZ738008A (en) Tigit-binding agents and uses thereof
MD4716C1 (ru) Антитела анти-LAG3 и антигенсвязывающие фрагменты
EA201991720A1 (ru) Антитела к альфа-синуклеину и их применения
EA201791485A1 (ru) Анти-cd47-антитела и их применения
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
JO3532B1 (ar) الأجسام المضادة لمضاد انترلوكين-33 واستعمالاتها
EA202191380A1 (ru) Антитела к альфа-синуклеину и их применение
EA201890305A1 (ru) Гуманизированные или химерные cd3-антитела
GEP201706794B (en) Bi-specific monovalent fc diabodies that are capable of binding cd32b and cd79b and uses thereof
PH12017501522B1 (en) Antibodies to tau and uses thereof
PH12017501077A1 (en) Compositions and methods for antibodies targeting bmp6
MX2017003211A (es) Anticuerpos anti-met y composiciones.
EA201592203A1 (ru) Способы лечения таупатии
EA201792220A1 (ru) Опосредуемая антителом нейтрализация вируса чикунгунья
EA201792561A1 (ru) Антитела, нацеленные на морфогенетический белок кости 9 (bmp9), и способы их применения
EA201890434A1 (ru) Антитела к cd154 и способы их применения
MX2022002635A (es) Anticuerpos anti proteina similar a angiopoyetina 4 y metodos de uso.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
PH12018500445A1 (en) Use of anto-cd40 antibodies for treatment of lupus nephritis
EA201890629A1 (ru) Применение антител к cd40 для лечения волчаночного нефрита

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM RU